NACE Non-invasive prenatal test

NACE
Benefits
Indications

What is NACE?

NACE is a non-invasive prenatal screening test for the most frequent chromosomal abnormalities. The test is non-invasive, meaning that there is no risk to the fetus.

A simple blood draw from the mother allows free fetal DNA circulating in the maternal bloodstream to be detected via next-generation sequencing (NGS) technology and our proprietary bioinformatic analysis tool.

Methodology

What does NACE detect?

NACE detects abnormalities in chromosomes 21, 18, 13 and the most common anomalies in the sexual chromosomes (X and Y).
NACE 24 analyzes all chromosomes

NACE can be used for:

Single pregnancies
Twin pregnancies
Can give results with fetal fraction under 4%
Natural conception
IVF

Egg donation
Women of all ages
Women of all ethnicities
Women of all body mass index
Suitable for cases of consanguinity

Why use a non-invasive prenatal test

Prevent the need for 98% of invasive tests in patients at risk for trisomy 21 (Down Syndrome)
Reduces the number of miscarriages caused by amniocentesis or chorionic villus sampling (CVS)
Can give results with fetal fraction under 4%
NACE has the highest informativity rate in the market: we obtain results for 99.9% of the analyzed samples
More reliable than 1st trimester combined screening. The false positive rates of conventional tests, including biochemical screening, mean that 1 in every 20 women who test positive for Down syndrome will actually be carrying a healthy baby.
Avoid a false sense of security: Of every 20 women carrying a baby with Down syndrome, 3 will test negative by biochemical screening.

Who is NACE suitable for?

Several scientific studies support the use of non-invasive prenatal testing for all pregnant women.

An abnormal result in their first-trimester screen.
A previous Down´s syndrome pregnancy
A suspicious ultrasound finding.

(Gregg, et al. Genet Med. 2016)

Test Limitations

cfDNA screening is considered a screening test and not a diagnostic test.
False non-invasive prenatal screening (NIPT) results: fetoplacental mosaicism, maternal chromosomal abnormalities, vanishing twin syndrome and/or errors associated with the procedures.
Low-molecular-weight heparin can interfere with the analysis. If the patient is taking heparin during pregnancy, the recommendation is to perform the blood draw before heparin administration.

Documentation

Specialists’ documents

Clinical Sheets

Download

Scientific evidence

Relevant related studies:

Title: Fetal sex determination in twin pregnancies using cell free fetal DNA analysis

Authors: Milan M, Mateu E, Blesa D, Clemente-Ciscar M, Simon C

Publication: Prenat Diagn. 2018 Apr 23. doi: 10.1002/pd.5274.

PMID: 29683524

Title: Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics

Authors: Gregg A R, Skotko B G, Benkendorf J L, Monaghan K G, Bajaj K, Best R G, Klugman S, Watson M S

Publication: Genet Med. 2016 Oct;18(10):1056-65. doi: 10.1038/gim.2016.97. Epub 2016 Jul 28.

PMID: 27467454

Title: DNA sequencing versus standard prenatal aneuploidy screening

Authors: Bianchi D W, Parker R L, Wentworth J, Madankumar R, Saffer C, Das A F, Craig J A, Chudova D I, Devers P L, Jones K W, Oliver K, Rava R P, Sehnert A J, CARE Study Group

Publication: N Engl J Med. 2014 Feb 27;370(9):799-808. doi: 10.1056/NEJMoa1311037.

PMID: 24571752

Title: Screening for fetal aneuploidies at 11 to 13 weeks

Author: Nicolaides K H

Publication: Prenat Diagn. 2011 Jan;31(1):7-15. doi: 10.1002/pd.2637.

PMID: 21210475

If you're a little lost with this technical information...

Can we help you?

I’m not a health specialist

Igenomix and fertility

We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.

Learn more about Igenomix

Other services you may be interested in

ERA

Evaluates the endometrial receptivity

More information

PGT-A

Chromosomally normal
embryos selection

More information

CGT

Determines the risk of having a child with a genetic disease

More information

Screens for the most common chromosomal abnormalities without risk to your child

Highest informativity rate in the market: we obtain results for 99.9% of the analyzed samples

Available from week 10 of pregnancy

Reduces unnecessary amniocentesis

What is NACE?

Methodology

What does NACE detect?

NACE can be used for:

Why use a non-invasive prenatal test

Who is NACE suitable for?

Test Limitations

Clinical Sheets

Relevant related studies:

Can we help you?

Igenomix and fertility

ERA

PGT-A

CGT

NACE Non-invasive prenatal test

Non-invasive prenatal screening helps to avoid unnecessary amniocentesis

Screens for the most common chromosomal abnormalities without risk to your child

Highest informativity rate in the market: we obtain results for 99.9% of the analyzed samples

Available from week 10 of pregnancy

Reduces unnecessary amniocentesis

What is NACE?

Methodology

What does NACE detect?

NACE can be used for:

Why use a non-invasive prenatal test

Who is NACE suitable for?

Test Limitations

Clinical Sheets

Relevant related studies:

Can we help you?

Igenomix and fertility

Other services you may be interested in

ERA

PGT-A

CGT

Igenomix is in the media